Aclarion, Inc. (ACONW) stock
ACONWNasdaqServices-Medical LaboratoriesFiscal year ends December 31Also trades as ACON
$0.02+0.00 (0.00%)
Close on Oct 30, 2026Market cap $5.62MP/E –Yield –
Aclarion ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Aclarion's ebitda for the twelve months ending Jun 30, 2026 was -$9.47M. For fiscal 2025 it was -$6.82M. The highest annual figure on record is -$2.77M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.82M | – |
| FY2024 | Dec 31, 2024 | -$5.32M | – |
| FY2023 | Dec 31, 2023 | -$4.71M | – |
| FY2022 | Dec 31, 2022 | -$5.42M | – |
| FY2021 | Dec 31, 2021 | -$2.77M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.84M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.93M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.77M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.68M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.44M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.75M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.25M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.09M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.23M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.08M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.12M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.37M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.14M | – |
| Q4 FY2022 | Dec 31, 2022 | -$903.19K | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.60M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.02M | – |
| Q3 FY2021 | Sep 30, 2021 | -$751.53K | – |
| Q2 FY2021 | Jun 30, 2021 | -$577.35K | – |
| Q1 FY2021 | Mar 31, 2021 | -$415.69K | – |